Summary of COVID-19 vaccine AEFI reports received in Saskatchewan

As of June 19, 2022, a cumulative total of 1,297 reports have been received, following 2,508,534 doses of COVID-19 vaccines administered, with a reporting rate of 0.52 per 1,000 doses administered (0.052% of all doses administered). Refer to Tables 1 and 2 for more details.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of June 19, 2022

	Pfizer 12+	Moderna	AstraZeneca	COVISHIELD	Janssen	Pfizer 5-11	Novavax	All combined
Total number of doses administered	1,786,550	518,251	74,923	17,023	1,869	109,610	308	2,508,534
Total number of AEFI reports received	832	312	113	25	3	11	1	1,297
Number of non-serious reports	771	300	95	24	2	10	1	1,203
Number of serious reports¹	61	12	18	1	1	1	0	94
Proportion of serious AEFI reports	7%	4%	16%	4%	33%	9%	0%	7%
AEFI reporting rate per 1,000 doses administered	0.47	0.6	1.51	1.47	1.61	0.1	3.4	0.52
Serious AEFI reporting rate per 1,000 doses administered	0.03	0.02	0.24	0.06	0.54	0.01	0	0.04

¹Serious criteria includes an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation.

Table 2: Cumulative Frequency of AEFIs Reported

Adverse event type	# of events
Rashes (all)	245
Anesthesia/paresthesia	216
Edema (allergic, not injection site)	208
Injection site reactions	197
Vomiting/diarrhea/nausea	142
Anaphylaxis	80
Headache	67
Chest tightness	65
Arthralgia/arthritis/joint pain	44
Malaise/lethargy	42
Fever	35

There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of June 19, 2022, 3 VITT/TTS, 33 myocarditis/pericarditis, 0 GBS and 0 CLS cases have been reported in Saskatchewan.

Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of June 19, 2022

Table 2: Cumulative Frequency of AEFIs Reported

We need your feedback to improve saskatchewan.ca. Help us improve